Compare Merck & Co., Inc. (MRK) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Msci Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Msci Inc trades at $565.12 (market cap $40.38B). The key difference: Merck & Co., Inc. is far larger — about 8.7× Msci Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Msci Inc for 82 Days on average.
| MRK | MSCI | |
|---|---|---|
Market Cap | $351.28B | $40.38B |
Volume | 7,969,665 | 414,140 |
Sector | Health | Financials |
52-Week High | $156.43 | $643.83 |
52-Week Low | $82.49 | $511.84 |
Typical Hold Time | 98 Days | 82 Days |
Enterprise Value | $398.04B | $46.54B |
Dividend Yield | 2.39% | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
MSCI trades at $561.67, up 1.13% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $3.13B in 2025, with a high net income margin of 40.73%. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow from operations. Analyst consensus is strongly positive, with a $701.71 price target, supported by 74% buy ratings. Key developments include the completed acquisition of First Street, enhancing its climate risk analytics offerings.
The outlook for MSCI is favorable, driven by recurring revenue streams, high client retention, and growth in passive investing and private markets. Risks include high valuation multiples, significant long-term debt of $4.51B, and sensitivity to financial market cycles. The stock presents a long-term growth opportunity, but investors should monitor execution on earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
